Parenteral Delivery of Peptides and Proteins - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 590

In a nutshell, to make further progress in developing the technologies discussed here,
manufacturers face a number of important considerations, including scalability of the
technology and its production process, sterilization, assessment of regulatory aspects
of toxicology and long-term therapy, and appropriate in vivo models for both the par-
ticular P/P and delivery system under development. The consequences of introduc-
ing a new technology to the market is a genuine demand that remains a challenge for
manufacturers and formulation scientists.

Acknowledgment

The authors acknowledge the financial assistance from All India Council for
Technical Education and TIFAC CORE in NDDS, Government of India, New Delhi
for providing the research facilities to the team.

References

[1] Yingjuan L, Jun Y, Emanuela S. Issues related to targeted delivery of proteins and pep-
tides. AAPS J 2006;8:E466-78.
[2] Eva HM, Lene J. Alternative routes of administration for systemic delivery of protein
pharmaceuticals. Drug Discov Today Technol 2008;5:e89-94.
[3] Venter JC. The sequence of the human genome. Science 2001;291:1304-51.
[4] Lee HJ. Protein drug oral delivery: the recent progress. Arch Pharm Res 2002;25:572-84.
[5] Tauzin

B. Report: biotechnology medicines in development. Washington DC:

Pharmaceutical Research and Manufacturers Association; 2006.
[6] Snjezana S, Kevin S. Formulations for delivery of therapeutic proteins. Biotechnol Lett
2009;31:1-11.
[7] Walsh G. Biopharmaceutical benchmarks. Nat Biotechnol 2006;24:769-76.
[8] Chrastilova Z, Martina M, Vladimir K, Tomas M. Therapeutic application of peptides
and proteins: parenteral forever? Trends Biotechnol 2009;27:628-35.
[9] Johnson-Léger C, Christine AP, Greyce S, Jeffrey PS, Amanda E. Protein therapeutics-
lessons learned and a view of the future. Expert Opin Biol Ther 2006;6:1-7.
[10] Pettit DK, Gombotz WR. The development of site-specific drug-delivery systems for pro-
tein and peptide biopharmaceuticals. Trends Biotechnol 1998;16:343-9.
[11] Lee VH. Enzymatic barriers to peptide and protein absorption. Crit Rev Ther Drug
Carrier Syst 1988;5:69-97.
[12] Mingda B, Singh J. Degradation of luteinizing hormone releasing hormone in buccal,
liver, nasal and skin tissues. Int J Pharm 1988;175:269-73.
[13] Khaled A, Jagdish S. Smart polymer based delivery systems for peptides and proteins.
Recent Pat Drug Deliv Formul 2007;1:65-71.
[14] Jorgensen L, Moeller EH, van de WM, Nielsen HM, Frokjaer S. Preparing and evaluat-
ing delivery systems for proteins. Eur J Pharm Sci 2006;29:174-82.
[15] Pitt CG. The controlled parenteral delivery of polypeptides and proteins. Int J Pharm
1990;59:173-96.
[16] Yu T, Singh J. Biodegradable and biocompatible thermosensitive polymer based inject-
able implant for controlled release of protein. Int J Pharm 2009;365:34-43.